The higher levels of PlGF in patients with SRC compared with patients with HUS and patients with MHT are in favor of an inflammation-fueled process, possibly leading to endothelial injury triggering or sustaining SRC. The gene discussed is PGF; the disease is hemolytic-uremic syndrome.